# Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

> **NCT07593248** · — · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 2000 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07593248
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2031-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593248, "Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07593248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*